August 13, 2015 | Teva Pharmaceutical Industry’s new drug application for Huntington’s Disease medication was approved by the US Food & Drug Administration. The drug, SD-809, was approved for the treatment of chorea, a neurological disorder associated with Huntington’s Disease. The trial drug SD-809 was added to Teva’s portfolio after the pharmaceutical company acquired Auspex for $3.2 billion in May 2015. Teva was founded in 1901 and is headed by CEO Erez Vigodman.
Subscribe to NoCamels weekly newsletter and get our top stories
Related posts

Israel Invests Millions To Help AI Comprehend Hebrew, Arabic
September 21, 2023

Cybersecurity Startup Cato Raises $238M With $3B Valuation
September 21, 2023

Israel, UK Ink Deal For Greater Innovation Collaboration
September 21, 2023

ALS Drug Receives Patent In Israel, Europe, Japan
September 20, 2023
Facebook comments